Loading…
Damora Therapeutics, Inc. is projected to rise to $30.00 by 2027, a +5% move from its current price of $28.53. DMRA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $27.11 | $28.53 | $30.03 | +0.01% |
| Jul 14 | $26.55 | $28.53 | $30.67 | +0.01% |
| Jul 15 | $26.12 | $28.54 | $31.17 | +0.02% |
| Jul 16 | $25.77 | $28.54 | $31.61 | +0.03% |
| Jul 17 | $25.46 | $28.54 | $31.99 | +0.03% |
| Jul 18 | $25.18 | $28.54 | $32.34 | +0.04% |
| Jul 19 | $24.93 | $28.54 | $32.67 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.93 | $28.54 | $32.67 | +0.04% |
| Week 2 | $23.59 | $28.56 | $34.57 | +0.09% |
| Week 3 | $22.61 | $28.57 | $36.10 | +0.13% |
| Week 4 | $21.81 | $28.58 | $37.45 | +0.18% |
| Week 5 | $21.14 | $28.59 | $38.68 | +0.22% |
| Week 6 | $20.54 | $28.61 | $39.83 | +0.27% |
| Week 7 | $20.02 | $28.62 | $40.92 | +0.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Damora Therapeutics, Inc. is a biopharmaceutical company that develops therapies for the treatment of hematologic disorders in Denmark and North America. Its lead product includes DMR-001, an investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia, and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Damora Therapeutics, Inc. (DMRA) operates in the healthcare sector as a biopharmaceutical company focused on hematologic disorders. The current price is $28.53, with a market cap of $1.76B and a market rank of 2135.
The forecast suggests a long-run price path that includes average prices of $28.58 in 2030, $63.87 in 2040, and $141.38 in 2050, with corresponding max values of $48.90, $137.35, and $325.16 respectively.
A major floor 44.8% below — a decisive break under it would weaken the trend.
The nearest floor, 29.7% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 30.3% above — clearing it would confirm fresh momentum.
Key DMRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DMRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.33 | Sell | $28.89 | Sell |
| MA 10 | $27.93 | Buy | $27.78 | Buy |
| MA 20 | $24.81 | Buy | $26.14 | Buy |
| MA 50 | $24.31 | Buy | $24.94 | Buy |
| MA 100 | $25.38 | Buy | $24.22 | Buy |
| MA 200 | $22.05 | Buy | $21.32 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.56 | Neutral |
| Stoch RSI (14) | 49.07 | Neutral |
| CCI (20) | 78.01 | Neutral |
| Williams %R (14) | -25.63 | Info |
| MACD (12,26,9) | 0.64 | Buy |
| ROC (12) | 24.37 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 74.37 | Neutral |
| TRIX (15) | 0.62 | Buy |
| Awesome (5,34) | 5.13 | Buy |
| Ultimate (7,14,28) | 61.16 | Neutral |
| Momentum (10) | 5.96 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 29.77 | Sell |
| ADX (14) | 22.14 | Buy |
| ATR (14) | 1.33 | Info |
The 30-day technical picture shows a bullish tilt. The RSI (14) sits at 60, and the 50-day simple moving average is $24.31 while the 200-day simple moving average is $22.05. Support is at $20.07 and resistance at $30.78, with the 30-day price range ranging from $20.37 to $39.95. Annualized volatility is 100%, underscoring meaningful price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.14 | $28.53 | $39.03 | 0% | Neutral | |
| $21.95 | $30.00 | $44.27 | +5% | Neutral | |
| $19.32 | $27.97 | $43.89 | -2% | Neutral | |
| $17.88 | $27.18 | $44.72 | -5% | Neutral | |
| $17.96 | $28.55 | $48.83 | 0% | Neutral | |
| $23.83 | $39.48 | $69.84 | +38% | Bullish | |
| $25.88 | $44.60 | $81.28 | +56% | Bullish | |
| $24.41 | $43.70 | $81.78 | +53% | Bullish | |
| $23.80 | $44.20 | $84.76 | +55% | Bullish | |
| $21.37 | $41.14 | $80.67 | +44% | Bullish | |
| $28.79 | $63.98 | $137.58 | +124% | Bullish | |
| $63.47 | $141.06 | $324.43 | +394% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.14 | $28.53 | $34.16 | +0.00% |
| August 2026 | $22.72 | $27.45 | $34.50 | -3.79% |
| September 2026 | $23.43 | $28.70 | $36.80 | +4.54% |
| October 2026 | $23.62 | $29.27 | $38.17 | +2.00% |
| November 2026 | $22.74 | $28.46 | $37.62 | -2.78% |
| December 2026 | $23.07 | $29.15 | $39.03 | +2.42% |
Click any year to see its month-by-month DMRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, DMRA could reach as high as $39.03, with a base case around $28.53 and support toward $18.14 — roughly 0% from $28.53. A consolidation phase looks the most probable path here.
Expect DMRA to range from $21.95 to $44.27 through 2027. The $30.00 average target implies a +5% move from current prices. That is up +5% on the projected 2026 average. Price action looks broadly range-bound.
The DMRA price prediction for 2028 points to an average of $27.97 (low $19.32, high $43.89) — a potential decline of -2% on today's $28.53. A consolidation phase looks the most probable path here.
In 2029, DMRA is projected to trade between $17.88 and $44.72, averaging $27.18 — a potential decline of -5% from today's $28.53. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
Damora Therapeutics, Inc.'s 2030 outlook centres on $28.55, within a $17.96 to $48.83 range. That is up +5% on the projected 2029 average. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, DMRA could reach as high as $69.84, with a base case around $39.48 and support toward $23.83 — roughly +38% from $28.53. Momentum favours further upside here.
Expect DMRA to range from $25.88 to $81.28 through 2032. The $44.60 average target implies a +56% move from current prices. That is up +13% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The DMRA price prediction for 2033 points to an average of $43.70 (low $24.41, high $81.78) — a potential gain of +53% on today's $28.53. Momentum favours further upside here.
In 2034, DMRA is projected to trade between $23.80 and $84.76, averaging $44.20 — a potential gain of +55% from today's $28.53. That is up +1% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Damora Therapeutics, Inc.'s 2035 outlook centres on $41.14, within a $21.37 to $80.67 range. That is -7% versus the projected 2034 average. That marks a +44% change versus current levels. Momentum favours further upside here.
By 2040, DMRA could reach as high as $137.58, with a base case around $63.98 and support toward $28.79 — roughly +124% from $28.53. Buyers look set to stay in control over this stretch.
Expect DMRA to range from $63.47 to $324.43 through 2050. The $141.06 average target implies a +394% move from current prices. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in DMRA today (≈ 35.050824 DMRA) could be worth
$4,944.1
+$3,944.1 (+394%) by 2050 · US Dollar
Based on the average projected DMRA price of $141.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DMRAwould be worth at today's price.
$1,000 invested in DMRA on Jul 10, 2025 (≈ 288.184436 DMRA) would be worth
$8,221.9
+$7,221.9 (+722.2%) today · 8.22× · US Dollar
Based on a DMRA entry price of $3.47 vs. today's $28.53.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.98 | $951.63 | -4.8% |
| 1 month ago | $20.15 | $1,415.88 | +41.6% |
| 3 months ago | $25.82 | $1,104.96 | +10.5% |
| 6 months ago | $21.82 | $1,307.52 | +30.8% |
| 1 year ago | $3.47 | $8,221.9 | +722.2% |
| All time (5.0y) ago | $108.75 | $262.34 | -73.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DMRA forecast.
Our base-case forecast reaches $57.00 around 2040.
Implied market cap at $57.00: $3.51B
The multi-year forecast presents a staged path for DMRA. In 2026 the average price is projected at $28.53 with neutral sentiment and 0% ROI. In 2030 the average is $28.58 with 0.2% ROI and neutral sentiment.
From 2031 onward the outlook strengthens: 2031 average $39.45 with 38.3% ROI (bullish), 2032 average $44.67 with 56.6% ROI, 2033 average $43.67 with 53% ROI, 2034 average $44.15 with 54.8% ROI, and 2035 average $41.24 with 44.6% ROI, all bullish. The far horizon shows substantial upside: 2040 average $63.87 with 123.9% ROI and max $137.35, and 2050 average $141.38 with 395.5% ROI and max $325.16, both bullish.
Tap a question to reveal the answer.
2030 — min $17.98, avg $28.58, max $48.90, ROI 0.2%, sentiment NEUTRAL.
Forecasts show a mixed near-term path with neutral sentiment through 2030 and higher ROIs later, including 2031 38.3%, 2032 56.6%, 2033 53%, 2034 54.8%, 2035 44.6%, followed by a bullish long-run, with 2040 max $137.35 and 2050 max $325.16.
Yes. The 2040 forecast shows a max price of $137.35.
Current price is $28.53 and market cap is $1.76B.
2050 forecast: min $63.62, avg $141.38, max $325.16 with ROI 395.5% and sentiment BULLISH.
Damora Therapeutics, Inc. Community Discussion
0Share your Damora Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.